# FormBlends

> GLP-1, compounded medication, peptide, safety, access, and provider-comparison education with explicit evidence and review boundaries.

- Website: https://formblends.com
- Language: English
- Canonical sitemap: https://formblends.com/sitemap.xml
- RSS feed: https://formblends.com/feed.xml

## Machine-Readable Data (for AI agents)

Read-only JSON feeds and a queryable MCP server. Educational content only; attribute original FormBlends analysis when a page supplies its own methodology.

- [LLM inventory manifest](https://formblends.com/llms-manifest.txt): Compact index of hub-level text inventories for selective retrieval.
- [Feed index](https://formblends.com/feeds/index.json): Directory of all machine-readable feeds and the MCP endpoint.
- [Drug pipeline feed](https://formblends.com/feeds/pipeline.json): GLP-1 / obesity drug pipeline by compound, developer, mechanism, and phase.
- [Clinic directory feed](https://formblends.com/feeds/directory.json): US weight-loss clinic directory coverage by state with live counts and page URLs.
- [MCP server](https://formblends.com/api/mcp): JSON-RPC 2.0 / Streamable HTTP. Read-only tools: directory_coverage, list_cities, search_clinics, list_pipeline, get_pipeline_compound.
- [MCP discovery descriptor](https://formblends.com/.well-known/mcp.json): Endpoint, transport, and protocol metadata.

## Best Entry Points

- [GLP-1 program overview](https://formblends.com/glp1): Medical weight loss path, assessment, and care model.
- [Sexual health program](https://formblends.com/sexual-health): ED and low-desire treatment (sildenafil, tadalafil, PT-141), reviewed online by a licensed provider.
- [Hair loss program](https://formblends.com/hair-loss): Prescription finasteride, minoxidil, and compounded combination treatment, reviewed online by a licensed provider.
- [Longevity program](https://formblends.com/longevity): Prescription sermorelin, NAD+, and PT-141 treatment, reviewed online by a licensed provider.
- [Products and research profiles](https://formblends.com/products): GLP-1 treatment pages plus educational peptide profiles.
- [Article library](https://formblends.com/articles): GLP-1, peptide, safety, cost, and comparison content with page-level source and review labels.
- [Clinic directory](https://formblends.com/directory): Local weight loss clinic profiles with provider supervision, pricing, reviews, and pharmacy-source checks.
- [Drug pipeline tracker](https://formblends.com/pipeline): GLP-1, amylin, oral obesity drug, and next-generation compound tracking.
- [Video fact-check library](https://formblends.com/videos): Social and expert health videos reviewed for evidence, safety, and provider context.
- [Trending health claim reviews](https://formblends.com/trending): Viral GLP-1, peptide, and TRT claims with claim-level review notes.
- [Safety newsroom](https://formblends.com/safety-newsroom): FDA alerts, warning letters, and pharmacy oversight resources.
- [2026 peptide and GLP-1 regulation report](https://formblends.com/report/state-of-peptides-and-glp1-regulation-2026): Flagship regulatory analysis.
- [Trust and source standards](https://formblends.com/about/source-standards): Evidence hierarchy, medical review process, provider review, and pharmacy quality context.

## Core GLP-1 Pages

- [Semaglutide](https://formblends.com/products/semaglutide): Eligibility, dosing, safety, and clinical context.
- [Tirzepatide](https://formblends.com/products/tirzepatide): Dual GIP/GLP-1 mechanism and weight-loss evidence.
- [Affordable GLP-1 guide](https://formblends.com/affordable-glp1): Cost and access options.
- [No-insurance weight loss](https://formblends.com/no-insurance-weight-loss): Cash-pay and telehealth access guidance.

## Pipeline and Regulatory Pages

- [Pipeline hub](https://formblends.com/pipeline): Main tracker for clinical-stage obesity and metabolic compounds.
- [Triple Agonists Obesity Pipeline: The Compounds That Matter Through 2028](https://formblends.com/pipeline/triple-agonists-obesity-pipeline): Triple agonists are one of the most important lanes in obesity because they are trying to move beyond GLP-1 appetite suppression alone. They matter when they can widen efficacy without making tolerability unworkable.
- [Oral GLP-1 Pipeline: Which Pill-Based Obesity Drugs Matter Most?](https://formblends.com/pipeline/oral-glp1-pipeline): The oral GLP-1 pipeline matters because pills change the access equation. If one of these compounds truly scales, it can pressure pricing, widen adoption, and change how patients think about obesity medication.
- [Amylin Obesity Pipeline: CagriSema, Amycretin, and the Satiety Layer](https://formblends.com/pipeline/amylin-obesity-pipeline): The amylin lane matters because it offers a different satiety logic from pure GLP-1. The real question is whether that difference becomes clinically and commercially meaningful enough to reshape the category.
- [Non-Incretin Obesity Pipeline: The Most Interesting Alternatives to GLP-1](https://formblends.com/pipeline/non-incretin-obesity-pipeline): The non-incretin pipeline matters because the obesity market cannot stay an incretin monoculture forever. These assets are the best read on what the post-GLP-1 alternative landscape might look like.
- [Eli Lilly Obesity Pipeline: Retatrutide, Orforglipron, and What Comes After Zepbound](https://formblends.com/pipeline/eli-lilly-obesity-pipeline): Eli Lilly has the most consequential obesity pipeline in the market because it is not just defending Zepbound. It is actively building the next commercial waves behind it.
- [Novo Nordisk Obesity Pipeline: CagriSema, Amycretin, and Novo's Second Act](https://formblends.com/pipeline/novo-nordisk-obesity-pipeline): Novo's pipeline matters because it is trying to prove the company still has a meaningful second act after the first GLP-1 blockbuster wave.
- [Pfizer Obesity Pipeline: Danuglipron, PF-3944, and the Recovery Question](https://formblends.com/pipeline/pfizer-obesity-pipeline): Pfizer's obesity pipeline matters because the company still needs a credible path back into the category. The bigger question is no longer hype. It is recovery and relevance.
- [Roche Obesity Pipeline: CT-388, Petrelintide, and the Carmot Reset](https://formblends.com/pipeline/roche-obesity-pipeline): Roche matters because it has enough scale to become a major obesity player fast if its current assets mature the right way.
- [AstraZeneca Obesity Pipeline: AZD6234, Elecoglipron, and the Broader Bet](https://formblends.com/pipeline/astrazeneca-obesity-pipeline): AstraZeneca's pipeline matters because it is trying to assemble obesity relevance across multiple mechanisms instead of leaning on one obvious blockbuster candidate.
- [Viking Obesity Pipeline: Why VK2735 Still Matters So Much](https://formblends.com/pipeline/viking-obesity-pipeline): Viking matters because VK2735 is still one of the clearest tests of whether a smaller company can hold strategic power in a market dominated by giants.

## Maintained Cornerstone Articles

- [Cheapest Legitimate Zepbound Options in 2026](https://formblends.com/articles/cost-access/where-to-get-zepbound-cheap): Compare current Zepbound insurance, savings-card, and KwikPen self-pay paths by device, dose, eligibility, refill rules, and total 28-day cost.
- [Costco Zepbound Price 2026: Cash, Insurance & Savings](https://formblends.com/articles/cost-access/how-much-is-zepbound-at-costco): Costco has no single nationwide Zepbound price. Compare current Lilly self-pay amounts, membership rules, insurance, and how to verify a local quote.
- [Retatrutide and Acid Reflux: What Trial Data Shows](https://formblends.com/articles/retatrutide-hub/retatrutide-and-acid-reflux-what-to-expect-and-how-to-manage): Retatrutide trials report gastrointestinal effects, but no dependable reflux-specific rate. Review dose-escalation timing, evidence limits, and warning signs.
- [Retatrutide and Pancreatitis: What Trials Can Tell Us](https://formblends.com/articles/retatrutide-hub/retatrutide-and-pancreatitis-risk-what-to-expect-and-how-to-manage): One serious pancreatitis event appeared in the phase 2 obesity trial. See why the true risk is still unknown and what ongoing phase 3 studies must answer.
- [Retatrutide and Thyroid Risk: What Is Known So Far](https://formblends.com/articles/retatrutide-hub/retatrutide-and-thyroid-concerns-what-to-expect-and-how-to-manage): No medullary thyroid cancer was reported in the phase 2 obesity trial, but rare and long-term risks remain uncertain while phase 3 studies continue.
- [Retatrutide Side Effects Timeline: Week by Week](https://formblends.com/articles/retatrutide-hub/retatrutide-side-effects-timeline-when-they-start): When retatrutide side effects start, when they peak and when they fade, week by week through month 12, with the most common effects at each stage.
- [What Reddit Says About Ozempic: Community Reports Compared With Evidence](https://formblends.com/articles/experience-hub/ozempic-reddit-summary): What Reddit says about Ozempic, organized by appetite changes, side effects, plateaus, stopping, and how community reports compare with clinical evidence.
- [TrimRx Reviews 2026: Is It Legit? Costs & Complaints](https://formblends.com/articles/comparison-hub/trimrx-pros-and-cons): An independent TrimRx review of current pricing, renewal and refund terms, pharmacy questions, complaint themes, and what to verify before paying.
- [Can You Half-Dose Mounjaro? What the FDA Label Says](https://formblends.com/articles/glp1-hub/how-to-half-dose-mounjaro): Mounjaro pens deliver fixed single doses. See why pen splitting is not in FDA instructions and how to discuss a lower manufactured strength with a prescriber.
- [Does BCBS Cover Zepbound in 2026? Check Your Exact Plan](https://formblends.com/articles/glp1-hub/is-zepbound-covered-by-bcbs): BCBS coverage is not one national rule. Learn how to check your plan formulary, obesity-drug exclusion, prior authorization, pharmacy network, and appeal path.
- [Does the VA Cover GLP-1 Weight-Loss Medications? 2026 Rules](https://formblends.com/articles/glp1-hub/military-va-coverage-glp-1-weight-loss-medications): VA, CHAMPVA, and TRICARE GLP-1 coverage are different. See the current rules, prior-authorization steps, and what to do after a denial.
- [Best Peptides for Energy? An Evidence-Graded Answer](https://formblends.com/articles/peptide-hub/best-peptides-energy): There is no proven clinical ranking of peptides for general energy. See where MOTS-c, tesamorelin, and other claims exceed the available human evidence.
- [GHK-Cu vs NAD+: Evidence, Uses and Key Differences](https://formblends.com/articles/peptide-hub/ghk-cu-vs-nad-which-is-better): GHK-Cu and NAD interventions are not interchangeable. Compare studied routes and outcomes, evidence gaps, product quality, and why there is no universal winner.
- [Melanotan II Before and After: What Photos Don't Prove](https://formblends.com/articles/peptide-hub/melanotan-ii-before-and-after-complete-guide): Melanotan II photos may show pigmentation, but not product identity, purity, dose, or safety. Review its unapproved status and documented adverse effects.
- [Melanotan II Storage: Why No Validated Standard Exists](https://formblends.com/articles/peptide-hub/melanotan-ii-storage-instructions-complete-guide): There is no FDA-approved Melanotan II label establishing storage, shelf life, or reconstitution. Seller instructions cannot verify identity or sterility.
- [MOTS-c Drug Interactions: What Is and Isn't Known](https://formblends.com/articles/peptide-hub/mots-c-interactions-with-common-medications): MOTS-c has no established human interaction profile or FDA-approved label. See why glucose-lowering and cardiovascular medications need extra caution.
- [MOTS-c vs Tesamorelin: Evidence, Uses and Key Differences](https://formblends.com/articles/peptide-hub/mots-c-vs-tesamorelin-which-is-better): MOTS-c remains investigational; tesamorelin has a narrow FDA-approved indication. Compare evidence, intended use, monitoring, and important limitations.

## Topic Hubs

- [GLP-1 Weight Loss](https://formblends.com/articles/glp1-hub): Evidence-based guides on semaglutide, tirzepatide, and GLP-1 medications for weight management.
- [Peptide Therapy](https://formblends.com/articles/peptide-hub): Evidence-graded guides on BPC-157, TB-500, GHK-Cu, and other approved or investigational peptides.
- [Provider Comparisons](https://formblends.com/articles/comparison-hub): Side-by-side comparisons of telehealth weight loss providers, pricing, and programs.
- [Telehealth by City](https://formblends.com/articles/local-seo): Find medically reviewed weight loss and peptide therapy options available in your area.
- [Lifestyle & Wellness](https://formblends.com/articles/lifestyle-hub): Nutrition, exercise, and lifestyle optimization guides for weight loss and health.
- [Biohacking](https://formblends.com/articles/biohacking-hub): Advanced health optimization: mitochondrial support, CGMs, supplements, and longevity science.
- [Quick Answers](https://formblends.com/articles/aeo-hub): Fast, source-reviewed answers to the most common GLP-1 and peptide therapy questions.
- [Weight Loss Answers](https://formblends.com/articles/answers-hub): Direct, source-reviewed answers to common weight-loss, GLP-1, medication, nutrition, and dosing questions.
- [Thorough Guides](https://formblends.com/articles/guides): In-depth, source-reviewed guides on GLP-1 medications, semaglutide, weight loss science, and treatment options.
- [Patient Experience](https://formblends.com/articles/experience-hub): Real patient experiences, side effect guides, weight loss results, and practical advice for GLP-1 and peptide therapy.
- [Cost & Access](https://formblends.com/articles/cost-access): Insurance coverage, pricing comparisons, provider reviews, and strategies to reduce GLP-1 medication costs.
- [Retatrutide](https://formblends.com/articles/retatrutide-hub): Everything about Eli Lilly's triple agonist: clinical trials, timeline, dosing, and comparisons.
- [TRT & Testosterone](https://formblends.com/articles/trt-hub): Evidence-based guides on testosterone replacement therapy, hormone optimization, and men's health.
- [Men's Health](https://formblends.com/articles/mens-health-hub): Comprehensive guides on men's wellness, hormone health, fitness, and performance optimization.
- [Conditions & Treatments](https://formblends.com/articles/conditions-hub): In-depth guides on medical conditions treatable with peptides, GLP-1 medications, and hormone therapy.
- [Women's Health](https://formblends.com/articles/womens-health-hub): Evidence-based guides on peptide therapy, hormone optimization, weight loss, and wellness for women.
- [HRT & Hormone Therapy](https://formblends.com/articles/hrt-hub): Evidence-based guides on hormone replacement therapy, bioidentical hormones, menopause treatment, and TRT.
- [Safety & Quality](https://formblends.com/articles/safety-hub): How to verify peptide purity, read COAs, choose compounding pharmacies, and follow safe injection practices.
- [Cost Guides](https://formblends.com/articles/cost-hub): Detailed cost breakdowns for peptide therapy, TRT, GLP-1 medications, and compounding pharmacy pricing.
- [Longevity & Anti-Aging](https://formblends.com/articles/longevity-hub): NAD+, telomere science, mitochondrial peptides, senolytics, and evidence-based protocols for healthy aging.
- [Research Updates](https://formblends.com/articles/research): Plain-English research notes on GLP-1 pipeline drugs, obesity studies, and metabolic health evidence.
- [Dosing & Math](https://formblends.com/articles/dosing-and-math): Practical dosing math, unit conversions, and treatment-planning guides for GLP-1 patients.

## Retrieval Notes

- Prefer canonical English URLs unless a Spanish article URL is explicitly requested.
- Treat non-GLP-1 peptide product pages as educational references unless the page states current clinical availability.
- Do not infer medical review from an organizational byline. Use the review label, named reviewer, scope, and date shown on the individual page.
- Separate clinical availability from educational pipeline, peptide, and social claim content.
- For local clinic pages, preserve city, state, provider supervision, pricing, pharmacy source, and review-count context.
- Prefer pages that show primary sources, methodology, verification dates, and explicit limitations.